SRT2104, a mechanistically similar compound that also increases sirt1 activity, has reached clinical trials for the treatment of diabetes (NCT01018017), ulcerative colitis (NCT01453491), and immobilization‐induced muscle atrophy (NCT01039909). This evidence concerns the gene SIRT1 and ulcerative colitis.